CoChat
Sign Up
Cited by 125Fatty Acid Research and HealthLipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)

Oikawa, Shinichi, Yokoyama, Mitsuhiro, Origasa, Hideki, Matsuzaki, Masunori, Matsuzawa, Yuji, Saito, Yasushi, Ishikawa, Yuichi, Sasaki, Jun, Hishida, Hitoshi, Itakura, Hiroshige, Kita, Toru, Kitabatake, Akira, Nakaya, Noriaki, Sakata, Toshiie, Shimada, Kazuyuki, Shirato, Kunio·2009·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2009.03.029
Open this paper in CoChat — free account

Abstract

Background JELIS was a large-scale clinical trial that investigated the effects of eicosapentaenoic acid (EPA) on coronary artery disease (CAD). In this paper, the data of patients registered in JELIS were analysed to compare the incidence of CAD between patients with impaired glucose metabolism (IGM) and normoglycemic (NG) patients. The effect of EPA on the incidence of CAD in patients with IGM was also assessed.Methods The 18,645 hypercholesterolemic patients registered in JELIS were divided into two groups. One group consisted of patients with IGM (n=4565), which included the patients who had diabetes mellitus and patients who had a fasting plasma glucose of 110mg/dL or higher, either at the time of registration or after 6 months. The other group consisted of NG patients (n=14,080). CAD incidence of the two groups over the average 4.6-year follow-up period was compared, and the effect of EPA was assessed.Results Compared to NG patients, IGM patients had a significantly higher CAD hazard ratio (1.71 in the non-EPA group and 1.63 in the EPA group). The treatment with EPA resulted in a 22% decrease in the CAD incidence (P=0.048) in IGM patients and an 18% decrease (P=0.062) in NG patients.Conclusions It was found that the CAD risk in IGM patients is higher than in NG patients, and that highly purified EPA is very effective in decreasing the incidence of CAD among Japanese IGM patients, even though the intake of fish is high.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2009.03.029

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

Sorted by citations

Items 101–125 of 125

Related

See all

Metadata

Authors
Oikawa, S., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., & Shirato, K.
Affiliations
  • Nippon Medical School (JP)
  • Hyogo Prefectural Awaji Medical Center (JP)
  • University of Toyama (JP)
  • Yamaguchi University (JP)
  • Kobe University (JP)
  • Fujita Health University (JP)
  • Ibaraki Christian University (JP)
  • Kyoto University (JP)
  • Nakamura Gakuen University (JP)
  • Jichi Medical University (JP)
Corresponding author
Oikawa, Shinichi
ORCID
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2009-10
Volume
206
Issue
2
Pages
535-539
ISSN
0021-9150 (ISSN-L)
DOI
10.1016/j.atherosclerosis.2009.03.029
OpenAlex
W2007616354
Cited by
125
References
30
Citations by year
2026: 1 · 2025: 2 · 2024: 11 · 2023: 7 · 2022: 5 · 2021: 5 · 2020: 4 · 2019: 8 · 2018: 14 · 2017: 7 · 2016: 11 · 2015: 8 · 2014: 7 · 2013: 12 · 2012: 12
FWCI
7.42
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Atherosclerosis (publishedVersion)
  • PubMed (publishedVersion)
Funders
Mochida Pharmaceutical Company
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
eicosapentaenoic acid, coronary artery disease, impaired glucose metabolism, hypercholesterolemia, diabetes mellitus, omega-3 fatty acids, cardiovascular risk reduction, fasting blood glucose
MeSH terms
Adult, Aged, Coronary Artery Disease, Diabetes Mellitus, Female, Humans, Hypercholesterolemia, Japan, Male, Middle Aged, Eicosapentaenoic Acid, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review